Sunitinib inhibits PD-L1 expression in osteosarcoma by targeting STAT3 and remodels the immune system in tumor-bearing mice
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Aim: Exploring the mechanisms of the combination therapy using VEGFR-TKI and immune checkpoint inhibitors might be useful to control the development of osteosarcoma. Materials & methods: The expression of PD-L1 and STAT3 in osteosarcoma were determined with western blot. Proliferation, migration and invasion were determined with CCK-8 and Transwell assays. Lung metastases, tumor growth, survival and immune cell populations were performed in tumor-bearing mice. Results: Sunitinib reduced the expression of PD-L1 by inhibiting the activation of STAT3 and suppressed the migration and invasion in osteosarcoma cells. Combination therapy reduced lung metastases, tumor growth, improved survival and reverse tumor microenvironment in tumor-bearing mice. Conclusion: Sunitinib inhibits PD-L1 expression by targeting STAT3 and remodels the immune system in tumor-bearing mice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PD-L1 downregulation by malignant and myeloid cells”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Duan et al., 2020
In the citing paper
“PD-L1 downregulation in osteosarcoma cells upon inactivation of STAT3”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Duan et al., 2020
Citations
Cites
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Yu, H., Kortylewski, M., & Pardoll, D. (2007) · Nature Reviews Immunology · doi:10.1038/nri1995 · Cited by 1,804
Functional significance of the perforin/granzyme cell death pathway
Trapani, J. A., & Smyth, M. J. (2002) · Nature Reviews Immunology · doi:10.1038/nri911 · Cited by 1,291
Osteosarcoma treatment – Where do we stand? A state of the art review
Luetke, A., Meyers, P. A., Lewis, I., & Juergens, H. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.11.006 · Cited by 1,234
Hegde, P. S., Karanikas, V., & Evers, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1507 · Cited by 1,000
Gao, Q., Wang, X.-Y., Qiu, S.-J., Yamato, I., Sho, M., Nakajima, Y., Zhou, J., Li, B.-Z., Shi, Y.-H., Xiao, Y.-S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1608 · Cited by 813
Research works printed but not linked: 2
- Hu X , CaoJ, HuWet al. Multicenter Phase II study of apatinib in nontriplenegative metastatic breast cancer. BMC Cancer2014(14), 820 (2009).
- 10.1186/s40425-015-0067-z · DOI · Paper page
Cited by
He, S., Zheng, L., & Qi, C. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02208-3 · Cited by 227
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 160
Immune checkpoints in osteosarcoma: Recent advances and therapeutic potential
Yang, W., Tang, F., Tu, C., Hornicek, F. J., Duan, Z., & Min, L. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215887 · Cited by 114
Macrophage Repolarization as a Therapeutic Strategy for Osteosarcoma
Anand, N., Peh, K. H., & Kolesar, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032858 · Cited by 100
Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies
Ji, Z., Shen, J., Lan, Y., Yi, Q., & Liu, H. (2023) · MedComm · doi:10.1002/mco2.308 · Cited by 82
Signal transducer and activator of transcription 3 signaling in tumor immune evasion
Zhang, L., Kuca, K., You, L., Zhao, Y., Musilek, K., Nepovimova, E., Wu, Q., Wu, W., & Adam, V. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107969 · Cited by 67
Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness
Panagi, M., Pilavaki, P., Constantinidou, A., & Stylianopoulos, T. (2022) · Theranostics · doi:10.7150/thno.72800 · Cited by 61
“CT/RT/ surgery OS [168, 317, 318] OS [88, 89, 319, 320]”
BackgroundHow Chemotherapy Affects the Tumor Immune Microenvironment: A Narrative Review
Merlano, M. C., Denaro, N., Galizia, D., Ruatta, F., Occelli, M., Minei, S., Abbona, A., Paccagnella, M., Ghidini, M., & Garrone, O. (2022) · Biomedicines · doi:10.3390/biomedicines10081822 · Cited by 54
“VEGF Bevacizumab Teff expansion; DC activation [73] Apatinib PD-L1 down-regulation [74] Sunitinib Treg depletion; MDSC depletion [75]”
BackgroundAdvancements in conventional cancer therapy combined with immunotherapy
Li, H., Han, S., Dong, C., & Liu, Z. (2024) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000067 · Cited by 45
Current progress and open challenges for applying tyrosine kinase inhibitors in osteosarcoma
Chen, C., Shi, Q., Xu, J., Ren, T., Huang, Y., & Guo, W. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01252-6 · Cited by 30
Liang, H., Cui, M., Tu, J., & Chen, X. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1394339 · Cited by 34
Advances and challenges in the treatment of osteosarcoma
Wang, X., Zhu, K., Hu, J., & Zhang, C. (2025) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2025.07.001 · Cited by 38
Zhu, H., Chen, D., Xie, X., Li, Y., & Fan, T. (2021) · Toxicon · doi:10.1016/j.toxicon.2021.04.024 · Cited by 29
Immunotherapy of osteosarcoma based on immune microenvironment modulation
Lian, H., Zhang, J., Hou, S., Ma, S., Yu, J., Zhao, W., Zhao, D., & Zhang, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1498060 · Cited by 31
Pathobiology and Molecular Pathways Implicated in Osteosarcoma Lung Metastasis: A Scoping Review
Bashir, A., Ismail, A., Mavadia, A., Ghose, A., Ovsepian, S. V., & Boussios, S. (2025) · Technology in Cancer Research & Treatment · doi:10.1177/15330338251359716 · Cited by 10
“25,27 The relationship between STAT3 and PD-L1 is further highlighted by the effects of sunitinib, a STAT3 inhibitor, that resulted in signi fi cant reductions in PD-L1 expression and OS progression, effectively remodeling the immune system by restoring immune surveillance.”
Enzyme-Dynamic Extracellular Vesicles for Metalloimmunotherapy of Malignant Pleural Effusions
Li, J., Yang, R., Dong, F., Qiu, Q., Jiang, Z., Ren, H., Zhang, C., Liu, G., Lovell, J. F., & Zhang, Y. (2024) · ACS Nano · doi:10.1021/acsnano.3c12375 · Cited by 9
Han, T., Wu, Z., Zhang, Z., Liang, J., Xia, C., & Yan, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1088732 · Cited by 8
“migration and invasion of osteosarcoma cells (Duan et al., 2020).”
Yang, M., Su, Y., Xu, K., Zheng, H. J., Cai, Y., Wen, P., Yang, Z., Liu, L., & Xu, P. (2024) · Journal of Immunology Research · doi:10.1155/2024/6595252 · Cited by 7
“Moreover, Sunitinib exhibits immunomodulatory effects in tumor-bearing animals by targeting STAT3 and inhibiting PD-L1 expression speci fi cally in OS [70].”
BackgroundKarakuş, F., Kuzu, B., Köstekci, S., & Tülüce, Y. (2024) · Current Computer - Aided Drug Design · doi:10.2174/0115734099307259240522093710 · Cited by 4
The lung pre‐metastatic niche in osteosarcoma: Mechanism and therapeutic intervention
Wang, D., Liu, T., Yin, B., Chang, Y., Hyon-U, P., Zhang, Y., & Li, H. (2025) · International Journal of Cancer · doi:10.1002/ijc.70188 · Cited by 2
Management of pediatric bone sarcomas
Elliott, L. A., Loeb, D. M., & Trucco, M. M. (2025) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001535 · Cited by 3
Chen, X., Li, X., Zhao, H., Qu, J., Li, X., Lin, C., & Yuan, Z. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1599496 · Cited by 2
“VEGFR-TKIs (e.g., apatinib, anlotinib, sunitinib) inhibit tumor proliferation, metastasis, and angiogenesis by promoting apoptosis (Wilhelm et al., 2004; Liu et al., 2017; Wang et al., 2019; Duan et al., 2020).”
Afanasyeva, K. A., Буданова, У. А., Sebyakin, Y. L., Gileva, A. M., Drozdova, M. G., & Арнольдовна, М. Е. (2025) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162025603660 · Cited by 2
Zhu, L., Liu, H., Zhang, S., fan, D., Yuan, X., Gao, X., & Nie, Y. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218803 · Cited by 1
Mori, K., Schmidinger, M., Egawa, S., Gust, K. M., & Shariat, S. F. (2021) · European Urology · doi:10.1016/j.eururo.2021.01.012
Principles of Immunotherapy and Novel Immunotherapeutic Agents for Pediatric Cancer Management
Morrison, Z. D., & Suliman, A. Y. (2025) · Springer eBooks · doi:10.1007/978-3-030-71113-9_39-1
Principles of Immunotherapy and Novel Immunotherapeutic Agents for Pediatric Cancer Management
Morrison, Z. D., & Suliman, A. Y. (2025) · Springer eBooks · doi:10.1007/978-3-031-76882-8_39
Lang, J., & Xiong, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1606825
“Sunitinib, a VEGFR-TKI, inhibits PD-L1 expression in osteosarcoma by targeting STAT3 and remodels the immune system in tumor-bearing mice (64).”
Sun, L., Lang, J., Zhang, W., & Xiong, Z. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1850680
“Both apatinib and sunitinib inhibit VEGFR2, thereby suppressing PD-L1 expression in osteosarcoma through STAT3 targeting (60, 61).”
Metadata
- Authors
- Duan, X. L., Guo, J. P., Li, F., Xiu, C., & Wang, H.
- Affiliations
- The Second Department of Orthopedic,The Affiliated Hospital of Beihua University, Jilin 132011, PRChina
- Beihua University (CN)
- Venue
- Future Oncology
- Publisher
- Informa UK Limited
- Published
- 2020-06-08
- Volume
- 16
- Issue
- 24
- Pages
- 1815-1824
- ISSN
- 1479-6694 (ISSN-L)
- 1744-8301
- OpenAlex
- W3033001024
- Cited by
- 30
- References
- 27
- Citations by year
- 2026: 2 · 2025: 11 · 2024: 5 · 2023: 3 · 2022: 5 · 2021: 3 · 2020: 1
- FWCI
- 1.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Future Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Jilin Provincial Department of Education
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Keywords
- sunitinib, osteosarcoma, PD-L1, STAT3, VEGFR inhibitors, immune checkpoint inhibitors, combination therapy, tumor microenvironment, lung metastasis, tumor cell migration and invasion
- MeSH terms
- Sunitinib, Animals, Bone Neoplasms, Cell Movement, Disease Models, Animal, Female, Humans, Osteosarcoma, Biomarkers, Gene Expression Regulation, Neoplastic, Immunophenotyping, Xenograft Model Antitumor Assays, Cell Line, Tumor, STAT3 Transcription Factor, Mice, Immunomodulation, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.